top of page

Buprenorphine X-Waiver Requirement Eliminated

SAMHSA (1/18) –– The 2023 Consolidated Appropriations Act [...] signed into law by President Biden on Dec. 29, 2022, amended the Controlled Substances Act to eliminate the requirement for qualified practitioners to first obtain a special waiver to prescribe medications such as buprenorphine for the treatment of opioid use disorder (OUD). This ends a decades-long requirement, originally put in place through the Drug Abuse Treatment Act (DATA) of 2000. With the new law, the patient limits associated with this special waiver also no longer apply. Read more

DEA (1/12) –– With the signing of the Consolidated Appropriations Act of 2023, Congress has eliminated the “DATA-Waiver Program.” [...] Medication for opioid use disorder helps those who are fighting to overcome opioid use disorder by sustaining recovery and preventing overdoses. The elimination of the X-Waiver will increase access to buprenorphine for those in need. Read more

0 views0 comments

Recent Posts

See All

SAMHSA [18-July] | SAMHSA is marking the one year-anniversary since the 988 Suicide and Crisis Lifeline was launched. In honor of one-year in service, SAMHSA’s 988 Lifeline team has updated the 988 Pa

bottom of page